The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.
The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in January 2007
Inhibitex, Inc. granted 3M an exclusive global license to use Clumping Factor A (ClfA), an MSCRAMM protein. 3M also received a license to use additional MSCRAMM protein targets for the development of other diagnostic products. MSCRAMM proteins are a family of proteins located on the surface of pathogenic organisms that represent viable targets for the development of therapeutic and diagnostic products. ClfA is an MSCRAMM protein that has been shown to be present on the vast majority of S. aureus strains.
Ciphergen and Quest Diagnostics plan to jointly develop a blood-based test for the detection of peripheral artery disease. The deal is the second of a three-part alliance the firms formed last year in which Quest will use Ciphergen’s SELDI-based ProteinChip technology to create the test. The first incarnation resulted in a test that triages ovarian cancer.
Dade Behring signed a license agreement with Radboud University Nijmegen Medical Centre granting Dade Behring with the exclusive rights for a new coagulation test called the Nijmegen Hemostasis Assay (NHA). The NHA is viewed by researchers to be important because it could provide insight into the whole blood-clotting process, including thrombophilia and fibrinolytic abnormalities, simultaneously in one test.
Diagnostic HYBRIDS released its D3 Ultra DFA Respiratory Virus Screening & Identification Kit. This second generation kit contains an increased number and better quality of antibodies for the detection of Influenza A, Influenza B, Parainfluenza 1, 2 and 3, Respiratory Syncytial Virus and Adenovirus. The one-step direct detection kit allows users to identify and differentiate seven major respiratory viruses in a 15-minute direct stain process, and it can be used for direct specimen testing as well as culture confirmation.
Olympus Life and Material Science Europa, GMBH (Olympus) and Saladax Biomedical, Inc. (SBI) entered into a development agreement to accelerate introduction of a blood test expected to help oncologists more effectively dose 5-fluorouracil (5-FU), a widely used chemotherapy agent. SBI is planning to adapt the first of a line of Personalized Chemotherapy Management assays for use on the Olympus AU400 clinical chemistry analyzer.
Otsuka Pharmaceutic Company introduced its Rapirun test, a rapid immunochromatographic assay that detects antibodies against Helicobacter pylori in urine. Test results can be determined by visual inspection in about 20 minutes.
Panacea Pharmaceuticals is developing PC Detect, a prostate cancer screening blood test meant to aid in the detection of prostate cancer in men 50 years and older who are referred for biopsy because of a tPSA > 4.0 ng/mL and/or an abnormal digital rectal exam. PC Detect will first be available from Panacea Laboratories, a division of Panacea Pharmaceuticals.
Roche Diagnostics signed a licensing agreement with Multilyte for access to Multilyte's patents for diagnostic assays. Roche intends to develop microarray-based immunoassays and other binding assay systems that will detect multiple analytes in a single reaction.
Vitalea Science received a Small Business Innovation Research grant from the NIH, to develop a medical diagnostic test to assess vitamin B12 malabsorption. The simple test intends to replace the Schillings test, the current standard, for assessing vitamin B12 malabsorption.
Product developments - December 2006
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links
Send mail to email@example.com with questions or comments about this web site.
Concept and Design Blue Page
Last modified: February 04, 2007